A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

This study is ongoing, but not recruiting participants.
Bausch & Lomb Incorporated
Information provided by:
Control Delivery Systems
ClinicalTrials.gov Identifier:
First received: March 20, 2002
Last updated: May 25, 2006
Last verified: December 2002
A study evaluating Retisert in patients with age-related macular degeneration

Condition Intervention Phase
Macular Degeneration
Drug: Retisert Implant
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Control Delivery Systems:

Study Start Date: November 2001

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00032396

United States, Massachusetts
Control Delivery Systems, Inc.
Watertown, Massachusetts, United States, 02472
Sponsors and Collaborators
Control Delivery Systems
Bausch & Lomb Incorporated
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00032396     History of Changes
Other Study ID Numbers: CDS FL-004 
Study First Received: March 20, 2002
Last Updated: May 25, 2006

Keywords provided by Control Delivery Systems:
Age-Related Macular Degeneration
Subfoveal Choroidal Neovascularization

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Fluocinolone Acetonide
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on January 19, 2017